Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gray Jodon"'
Autor:
Matthew J. Cortese, Wei Wei, Sebastian Cerdeña, Marcus P. Watkins, Marissa Olson, Gray Jodon, Jeff Kaiser, Bradley Haverkos, Mitchell E. Hughes, Esin Namoglu, Natalie S. Grover, Anson Snow, Victor Orellana-Noia, Magdalena Rainey, Mohammad Sohail, Joslyn Rudoni, Craig Portell, Timothy Voorhees, Daniel J. Landsburg, Manali Kamdar, Brad S. Kahl, Brian T. Hill
Publikováno v:
Leukemia & Lymphoma. 64:107-118
Patients with double- and triple-hit lymphomas (DHL/THL) have inferior outcomes with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), and higher-intensity regimens such as dose-adjusted (DA)-EPOCH-R are standard. Dose-i
Autor:
Gray Jodon, Meryl D. Colton, Diana Abbott, Anthony Cai, Bradley Haverkos, Rustain Morgan, Manali Kamdar
Publikováno v:
Clinical lymphoma, myelomaleukemia. 23(1)
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of relapsed/refractory (R/R) B-cell lymphomas, though certain patients do not respond to treatment or relapse afterwards. The purpose of this study is to determine patient va
Publikováno v:
Drugs & Aging. 35:409-421
Urothelial carcinoma, or bladder cancer, is a malignancy that most commonly affects older patients. The median age at diagnosis is 73 years, and care of these patients requires consideration not just of the disease-related factors such as stage and h
Autor:
Anthony Cai, Gray Jodon, Manali Kamdar, Meryl Colton, Diana Abbott, Brad M. Haverkos, Rustain Morgan
Publikováno v:
Blood. 138:3879-3879
Introduction: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of relapsed/refractory (R/R) B-cell lymphomas. Despite this improvement, a subset of patients do not respond to treatment or relapses afterwards. The purpose of
Autor:
Hong Li, Victor M. Orellana-Noia, Joslyn Rudoni, Jeff Kaiser, Marcus Watkins, Matthew J Cortese, Bradley M. Haverkos, Mitchell E. Hughes, Anson Snow, Brad S. Kahl, Natalie S Grover, Manali Kamdar, Mohammad Ahsan Sohail, Marissa Olson, Timothy J Voorhees, Sebastian Cerdena, Daniel J. Landsburg, Wei Wei, Craig A. Portell, Gray Jodon, Brian T. Hill, Magdalena A Rainey
Publikováno v:
Blood. 136:24-25
BACKGROUND: Central nervous system (CNS) relapse in systemic non-Hodgkin's lymphoma is associated with a guarded prognosis with a median survival of only 2-6 months. However, information regarding CNS relapse is still limited and there is no consensu